Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here’s the Bet She’s Making.

Many investors are keenly interested in growth stocks and want to know which are the most promising ones. Many also keep an eye on what famous investors are buying — or selling. One famous growth-stock investor is Cathie Wood, founder, CEO, and chief investment officer of Ark Invest, known for investing in companies with disruptive and innovative technologies.

A recent move Wood’s Ark Invest made is drawing some attention: Wood bought a bunch of Ionis Pharmaceuticals (NASDAQ: IONS) — a stock that trades down more than 28% year to date (as of Sept. 8).

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »

Meet Ionis Pharmaceuticals

Ionis Pharmaceuticals is known for its technologies that use small sequences of modified RNA to precisely target and interact with RNA and DNA to treat genetic diseases. The company has been around for 30-some years and offers medicines on the market and in its pipeline targeting neurologic and cardiometabolic diseases, among other conditions.

A key recent bit of news regarding Ionis is that in July, after the stock had more than doubled over the past year, it suffered a setback — due to disappointing news about two of its treatments in development.

Why would Cathie Wood buy Ionis now?

Ionis has a lot more going on than those two formulations. For example, in its second quarter, it reported revenue up 56% year over year, excluding a one-time payment. Its Tryngolza treatment is on track to achieve full-year revenue of $100 million to $110 million in 2026, while its Dawnzera treatment is on track to generate $110 million to $120 million in revenue. Both have international launches underway, which can boost revenue.

The company is also pivoting from being a company that mainly researches and develops treatments before partnering with deep-pocketed, bigger pharmaceutical companies to bring them to market — to one that does that latter work itself. That can pay off handsomely for the company, but it can also be costly.

These factors are likely among the reasons Cathie Wood is buying. It’s worth noting, too, that after first buying in 2016, per stockcircle.com, she has bought shares 14 more times and sold 22 times.

That’s a lot more trading activity than seems prudent for us individual investors. I have personally done best by investing in companies I believe in and then hanging on for years, if not decades.

Should you invest in Ionis?

You could buy the stock. There are ample reasons to be hopeful about it. And its share price and valuation now are lower than they were a few months ago. But keep in mind:

• The stock’s valuation doesn’t exactly look cheap at recent levels, with a price-to-sales ratio of 10.8, well above the five-year average of 8.1. (Of course, its prospects arguably look better now than five years ago.)

• The second quarter’s bottom line featured a net loss, not net income.

• It also featured a 23% drop in cash and equivalents, to about $2 billion.

• The stock offers no dividend, in case you’re a dividend aficionado.

Go ahead and take a closer look at Ionis Pharmaceuticals, but don’t just jump in because Cathie Wood did. Remember that she may well be selling some shares over the next quarter.

Should you buy stock in Ionis Pharmaceuticals right now?

Before you buy stock in Ionis Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ionis Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $414,015!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,385,459!*

Now, it’s worth noting Stock Advisor’s total average return is 960% — a market-crushing outperformance compared to 213% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of September 9, 2026.

Selena Maranjian has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Ionis Pharmaceuticals. The Motley Fool has a disclosure policy.

Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here’s the Bet She’s Making. was originally published by The Motley Fool